Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Other Non Operating Income: 2023-2024

Historic Other Non Operating Income for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to $1.1 million.

  • Contineum Therapeutics' Other Non Operating Income rose 2512.77% to $1.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.0 million, marking a year-over-year increase of 674.58%. This contributed to the annual value of $1.0 million for FY2024, which is 675.14% up from last year.
  • Latest data reveals that Contineum Therapeutics reported Other Non Operating Income of $1.1 million as of Q4 2024, which was up 3,435.29% from -$34,000 recorded in Q3 2024.
  • Contineum Therapeutics' Other Non Operating Income's 5-year high stood at $1.1 million during Q4 2024, with a 5-year trough of -$77,000 in Q2 2024.
  • For the 2-year period, Contineum Therapeutics' Other Non Operating Income averaged around $105,000, with its median value being -$35,000 (2023).
  • Examining YoY changes over the last 5 years, Contineum Therapeutics' Other Non Operating Income showed a top increase of 2,512.77% in 2024 and a maximum decrease of 1.32% in 2024.
  • Contineum Therapeutics' Other Non Operating Income (Quarterly) stood at -$47,000 in 2023, then surged by 2,512.77% to $1.1 million in 2024.
  • Its Other Non Operating Income was $1.1 million in Q4 2024, compared to -$34,000 in Q3 2024 and -$77,000 in Q2 2024.